

Acquisition of Boston Biomedical Inc.



February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.


Oncology Strategy and Acquisition Significance



Commitment to Oncology

Entering the Oncology Area Globally				
External Opportunity & Market Attractiveness	 High unmet medical needs/Necessity to pursue innovation Dynamic expansion of the role of medications Cancer as a chronic disorder, "Incurable" → "Treatable" R&D made possible through a rational approach Long term business, Market growth expected in the mid/long term Extended survival period, actualized needs for refractory, recurrent and metastatic cases 			
Change of Internal Environment	 (5) Establishing access to North American market (6) Next move after the launch of LATUDA (7) Strengthening the current development pipeline 			
Alignment with Mgmt Philosophy	(8) The challenge to provide cancer treatment is the mission of a R&D- oriented pharmaceutical company			
Compatibility with Global Strategy	 (9) A therapeutic area where a mid-sized company can succeed Intense competition but "Product-driven" therapeutic area Segmented market with the rise of personalized medicine (10) A typical specialty area Global business is possible with a small sales force 			

Initiative in Oncology Domain



3

Significance of BBI Transaction

Marks our commitment to the oncology business globally

- Acquisition of highly innovative development pipeline (BBI608 and BBI503)
 - Post-LATUDA candidate drugs
 - Expected growth driver from 2015 onward
- Acquisition of R&D personnel with high expertise and a human network in this area
- Securing an excellent drug discovery platform
- Utilizing BBI as a base to establish DSP's global oncology R&D organization



BBI Corporate Profile and Acquisition Benefits



BBI Business Profile



Company Overview

Description	Boston-area privately held biotechnology company focused on cancer stem cells
Representative	Chiang J. Li, M.D, FACP
Founded	November 2006
Headquarters	333 Providence Highway, Norwood, MA 02062
Employees	30

Board of Directors

Name	Position
Chiang J. Li, MD FACP	Chief Executive Officer & Chief Medical Officer
Joel Marcus	CEO, Alexandria Equities
Taro Inaba	General Manager, Healthcare and Cleantech Investment, Mitsui&Co.
William J. Rutter	Chairman of Synergenics, Founder and former chairman of Chiron

Boston Biomedical Inc. Appeal



Attractive Key Elements of BBI Emphasizing innovation as the essence of business Philosophy Entrepreneurial spirit essential to innovation Extensive experiences with clinical trials Human Many interesting R&D seeds and ideas **Resources** Small size, highly talented team (30 employees) Human Network Focused on cancer stem cell R&D and leading pipeline **R&D** Capabilities **Pipeline** BBI608 (In preparation for P3), BBI503 (Currently in P1) Located in Boston area where biotechnology companies, **R&D** center pharmaceutical companies and research institutions location focusing on cancer treatment are centered






Product Concept and Development Status of BBI608 and BBI503

First-in class, Molecular Targeted Drugs (small molecular compound, Oral agent)	
Excellent efficacy in monotherapy and combination with chemotherapy by inhibiting both growth of tumor cells and maintenance of cancer stem cells	
Highly safe, easy-to-use with existing chemotherapy. No particular hematologic toxicity observed	
First-in class, Molecular Targeted Drugs (small molecular compound, Oral agent)	
 Excellent efficacy in monotherapy and combination with chemotherapy by inhibiting both growth of tumor cells and maintenance of cancer stem cells by the different mechanism to BBI608. Highly safe, easy-to-use with existing chemotherapy. 	

Clinical Development Schedule

Product	Target Indication	Pre-clinical Phase1 Phase2 Phase3	
BBI608	Colorectal (2 nd /3 rd line, monotherapy)	P3 preparation	year
	Colorectal (2nd/3rd line, combo)	P2 ongoing 2015(earli	iest)
	Colorectal (1st line, combo)	Pre-P1b	
	Solid tumor (2 nd /3 rd line, combo with Paclitaxel)	P1b/2 ongoing	
BBI503	Solid tumor (monotherapy)	P1 ongoing	

Mechanisms of Action on BBI608 and BBI503



Transaction Summary and Financial Impact



Transaction Summary

Form:

- Acquisition of all shares of BBI
- Consideration:
 - Upfront Payment : US\$200 million
 - Development milestones : Maximum US\$540 million
 - Paid at pivotal trial commencement, application and approval
 - Sales Milestones : Maximum US\$1,890 million
 - Based on annual net sales in North America and Japan
 - Maximum amount is paid in case when annual net sales exceed US\$ 4 billion
- Closing (Planned)
 - April, 2012

Financial Impact

- Accounting Treatment :
 - Upfront Payment:
 - Upfront lump sum and accompanying expenses and the net amount between acquired assets and assumed liabilities is accounted for as goodwill
 - Development and Sales Milestones:
 - Recorded as goodwill at the time of payment, amortization conducted retroactively to the date of the acquisition
 - Period of Goodwill Amortization
 - Planned 20 year fixed amount amortization
- Impact to P/L:
 - Details of amortization of goodwill and intangible assets like In-process R&D will be announced when determined
- Funding of Acquisition
 - Own Fund

Disclaimer Regarding Forward-looking Statements

The statements made in this presentation material are forwardlooking statements based on management's assumptions and beliefs in light of information available up to the day of announcement, and involve both known and unknown risks and uncertainties.

Actual financial results may differ materially from those presented in this document, being dependent on a number of factors.

Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

